Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.58 |
| ▸ | POLB | P06746 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15409279 | 0.92 | TP53 (0.77) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411456 | 0.92 | MAPT (0.70) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411596 | 0.91 | MAPT (0.64) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411288 | 0.90 | MAPT (0.67) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411763 | 0.88 | MAPT (0.80) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411614 | 0.84 | RXFP1 (0.70) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15409599 | 0.82 | TP53 (0.77) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15409235 | 0.80 | RXFP1 (0.63) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL15425954 | 0.79 | RXFP1 (0.75) | TP53MAPTRXFP1POLBBLM | |
| SCHEMBL1021951 | 0.79 | MAPT (0.85) | TP53MAPTRXFP1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | NOX4, NOX1, CYBB | TP53 2443/4885MAPT 2698/4885RXFP1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.